On May 9, 2023 Alentis Therapeutics ("Alentis"), the Claudin-1 company, reported that it has been selected to receive a CHF 2.4M grant from the Swiss Accelerator project to further the development of ALE.C04 for Claudin-1 (CLDN1) positive cancers (Press release, Alentis Therapeutics, MAY 9, 2023, View Source [SID1234631225]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Of the original 752 applications, the Innosuisse Innovation Council selected 53 projects to receive funding across multiple industries with significant innovation potential. The total funding granted amounts to CHF 112M.

"We thank the Innosuisse Innovation Council for recognising Alentis’ work in oncology, and congratulate our fellow winners," said Dr. Roberto Iacone, CEO of Alentis.

About Innosuisse

Innosuisse is the Swiss Innovation Agency. Its mission is to promote science-based innovation in the interest of the economy and society in Switzerland. The core of Innosuisse funding is the support of innovation projects: innovative organizations such as companies and start-ups develop new services and products together with universities and research institutions. Please visit: www.innosuisse.ch

About ALE.C04

ALE.C04 is a first-in-class monoclonal antibody developed to target a unique CLDN1 epitope exposed in tumors. The antibody exerts its anti-tumor activity by mediating direct tumor cell killing via the effector function and by remodeling the extracellular matrix (ECM) thus allowing immune cells to reach the tumor. A Phase 1/2 first-in-human clinical trial of ALE.C04 is planned to start during the second half of 2023.